The EGF vaccine consists of a different approach when compared with other active immunotherapies. CIMAVax-EGF is built on the induction of a specific immune response, aiming to sequester EGF, a molecular driver of cancer cells proliferation. The significantly largest benefit of CIMAvax-EGF in the subpopulation of patients with high pre-treatment concentration of EGF is differentiating our cancer vaccine when compared with other modalities of active immunotherapy or targeted therapy. CIMAvax-EGF is a very safe drug that could be a feasible intervention for long-term control of Research.
Introduction
Lung cancer remains one of the leading causes of cancer-related death in men and women, provoking approximately 1.6 million deceases, 19 .4% of the total deaths per year, worldwide (1) . In Cuba for instance, lung cancer is the leading cause of death in both genders with more than one-quarter of all cancer deaths.
Non-small cell lung cancer (NSCLC) is the most common form of the disease (87%) and approximately 60% of the patients present advanced disease at diagnosis (2) .
Treatment of advanced NSCLC has undergone a rapid evolution along the last 30 years with three major advances: the platinum-based doublets, maintenance and second-line chemotherapy with docetaxel, pemetrexed or erlotinib and targeted therapies with small molecules such as gefitinib, erlotinib, afatinib, crizotinib or ceritinib for tumors with sensitizing mutations (3) (4) (5) (6) . Nevertheless, 1-year survival rate is approximately 35% for patients with wild type tumors whereas 5-year survival rate is still around 5% (2) .
Epidermal Growth Factor Receptor (EGFR) is overexpressed in approximately 40%-80% of non-small-cell lung cancers (7) . The oncogenic addiction of the malignancies to this signaling pathway triggers its inappropriate activation and promotes the uncontrolled growth, proliferation and survival of cancer cells (8) .
Thus, EGFR overexpression is associated with poor prognosis, lower survival and resistance to therapy (9) .
The EGF-based cancer vaccine CIMAvax-EGF is an active immunotherapy, intended to prevent binding of the endogenous EGF to the receptors, by inducing anti-EGF antibodies that clear the growth factor from circulation (10) .
CIMAvax-EGF is composed by human recombinant EGF coupled to a carrier
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Author Manuscript Published OnlineFirst on February 29, 2016; DOI: 10.1158/1078-0432.CCR- protein, recombinant P64. The EGF-P64 chemical conjugate is emulsified in Montanide, an oily adjuvant. The carrier protein and the adjuvant are required to break the tolerance against EGF, which is a self-protein. Previous phase I/II clinical trials evidenced the immunogenicity and safety of vaccination in patients with advanced stage NSCLC (11) (12) (13) . In a randomized phase 2 trial using CIMAvax-EGF as switch maintenance or second-line therapy versus best supportive care in subjects with stage IIIB or IV NSCLC, a trend toward survival benefit was found. Patients younger than 60 years, those with good antibody response against EGF and subjects in whom serum EGF concentration ([EGF]) decreased below a pre-established threshold, achieved a significant survival benefit with vaccination. Post-immune serum hampered the binding between EGF and EGFR in a radio-receptor assay and abrogated EGFR phosphorylation (14, 15) .
In the present article, we show the results of a randomized phase III trial in advanced NSCLC patients. The primary endpoint was overall survival, while safety, immunogenicity and serum EGF concentration before and after therapy, were secondary endpoints.
Patients and methods

Eligibility Criteria
Eligible patients were 18 years or older, with histologically or cytological proven stage IIIB/IV NSCLC and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. Patients with all histological NSCLC subtypes and life expectancy of at least 3 months were trial candidates. Other inclusion criteria included hemoglobin values above 90 g/L, leukocytes count ≥ 3.0 x 10 9 /L, platelets count ≥ 150 x 10 9 /L, serum glutamic oxalo-acetic transaminase (SGOT) and serum glutamate-pyruvate transaminase (SGPT) up to 2.5 times the upper institutional limit and creatinine, up to 2 times the upper institutional reference value. All patients received 4 to 6 cycles of platinum-based chemotherapy (mostly cisplatin/carboplatin in combination with vinblastine, etoposide or paclitaxel) and had stable disease or objective response.
The trial protocol, informed consent, investigator brochure and case report forms were approved by the ethic boards from all participating institutions and by the National Regulatory Agency. Informed consent was obtained from each subject before entering to the study. The study was done in compliance with the principles of Good Clinical Practices (according the International Conference of Harmonization) and the Declaration of Helsinki.
Treatment Schedule
Four to 6 weeks after finishing first-line chemotherapy, patients were randomly assigned (2:1) to the vaccine group, which received the EGF cancer vaccine plus best supportive care, or the control group, that was treated with best supportive care. Patients in the vaccine arm were given a low-dose of cyclophosphamide (200 mg/m 2 ) intravenously, 72 hours before the first immunization. Each vaccine dose was administered at 4 injection sites (2 deltoid and 2 gluteus regions), every two weeks for four doses (induction period) and then, monthly.
CIMAvax-EGF was manufactured at the industrial facility of the Centre for 
Measurements of Antibody Titers
Blood samples were collected at baseline (pre-treatment) and every 14 days for 60 days and monthly, thereafter. Anti-EGF antibody titers were measured through an enzyme linked immunosorbent assay (ELISA), as described in previous studies. Patients were classified in good antibody responders (GAR) if they developed anti-EGF antibody titers equal or higher than 1:4000, and supergood antibody responders (SGAR) if they reached anti-EGF antibody titers Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on February 29, 2016; DOI: 10.1158/1078-0432.CCR-15-0855 equal or higher than 1:64000. Those vaccinated patients that did not have titers above 1:4000 were classified as poor antibodies responders (PAR) (12) (13) (14) (15) . The two arms were well matched for baseline demographic and tumor variables such as sex, ethnic origin, age, smoking status, ECOG, disease stage, histology and response to initial chemotherapy (Table 1) 
CIMAvax-EGF Efficacy
In the safety population (patients receiving at least 1 CIMAvax-EGF dose), vaccinated patients had a survival benefit that did not reach statistical significance according the standard log-rank test (HR 0.82, 95% CI 0.661-1.03, Serum EGF was quantified in 188 patients. Mean and median EGF concentration was 1195 pg/ml and 873 pg/ml, respectively. There were not differences in the serum EGF levels between vaccinated and control patients.
Mean and median EGF concentration was 1194 pg/ml and 930 pg/ml for the vaccine arm and 1197 pg/ml and 820 pg/ml for controls (p=0.98).
Median EGF concentration (870 pg/ml) was established as a cutoff to classify patients in high or low [EGF] at enrollment, as pre-specified in the protocol.
Survival according [EGF] at baseline was evaluated in control and vaccinated
patients to preliminary assess the prognostic and predictive value of the referred biomarker.
In the control group, patients with high [EGF] had a worse survival as compared to patients with low [EGF] (HR 0.38 95% CI 0.20-0.70, p=0.002) (Figure 2A According to this retrospective analysis (predefined in the protocol), [EGF] above the 870 pg/ml threshold, could be a predictive biomarker of CIMAvax-EGF efficacy ( Figure 2B ). The interaction between EGF levels and treatment was checked and was statistically significant (p<0.0001). (Figure 3) . In control patients, there was no association between antibody titers and serum EGF.
Vaccination with CIMAvax-EGF induced anti-EGF antibodies and decreased EGF concentration in sera.
Anti
A subgroup exploration including the most important demographic and tumor variables was done in the safety population (Figure 4 ). In addition to high serum EGF concentration, patients with the largest benefit after vaccination were those bearing squamous cell carcinoma histology, smokers, and with stage IV. Table 2 and Supplementary Tables S2 and S3 ).
Long-term vaccination with CIMAvax-EGF was safe
Discussion
The treatment of advanced NSCLC has undergone a rapid evolution along the last 30 years: from a dark landscape in the 80s to the demonstration of survival gain after the combination of platinum doublets, maintenance and second line therapy with docetaxel, pemetrexed and erlotinib for patients with EGFR and ALK wild type tumors (3) (4) (5) .
Another big wave of improvement came with targeted therapies with tyrosine kinase inhibitors like gefitinib, erlotinib and afatinib for tumors carrying EGFR (19) . The median survival in patients with metastatic disease and defined mutations ranged from 23 to 27 months (20) . Unfortunately the population bearing EGFR or ALK mutations and thus, benefiting from the approved targeted therapies, is small (~15-20 %) (6) .
The next wave of progress is coming from immunotherapy. Long lasting responses have been reported after the use of the anti-PD1 antibodies (nivolumab, pembrolizumab) and the anti-PD1L antibodies (MPDL3280A, BMS936559, MEDI4736). Moreover, nivolumab has recently demonstrated to increase survival of patients bearing metastatic squamous and adenocarcinoma NSCLC that progressed on or after platinum-based chemotherapy, as compared with docetaxel (21, 22) . Pembrolizumab showed remarkable antitumor activity in patients with advanced NSCLC and PD-L1 expression in at least 50% of tumor cells (23) . FDA recently approved both checkpoint inhibitors for the treatment of metastatic NSCLC, as second line therapy.
Active immunization might also improve lung cancer survival, if the vaccine successfully triggers a strong immune response and if used in the right population. Clinical studies with three vaccine candidates in advanced population such as tecemotide, TG4010, and Belagenpumatucel-L had not meet their primary endpoint but showed possible benefits in patient subpopulations: for tecemotide, a potential role of vaccination was seen in patients treated with concurrent chemo-radiotherapy; for TG4010, the lymphocyte phenotype and concomitance with chemotherapy were reported as potential predictors of outcome and for Belagenpumatucel-L the number of circulating tumor cells appears to correlate with overall survival (24) (25) (26) The EGF vaccine consists of a different approach when compared with other active immunotherapies. CIMAvax-EGF is built on the induction of a specific immune response, aiming to sequester EGF, a molecular driver of cancer cells proliferation (11) (12) (13) (14) (15) . Its mechanism of action is based on the "hormone deprivation theory" that has proven to be effective for sexual hormones dependent tumors (10) . The rationale of CIMAvax-EGF is based on the finding that EGF concentration is higher in NSCLC patients than in normal donors. The preliminary role of [EGF] as a negative prognostic marker for advanced NSCLC reinforces the validity of the "removal" approach (9) .
In this phase III study, CIMAvax-EGF was very safe even in patients that received very prolonged vaccination (more than 2 years) and did not show Regarding efficacy, patients that received at least 4 doses of CIMAvax-EGF had a significant survival advantage. For active immunotherapy, where the target is the immune system and not the tumor, it is mandatory to administer a minimum number of vaccine doses to break the tolerance against self-antigens (27, 28) .
Moreover, in a post-hoc analysis in the safety population, CIMAvax-EGF significantly increased overall survival, when a weighted log-rank test was used.
The Harrington-Fleming test is very sensitive to detect a delayed effect in the survival curves, when the HR is not proportional. The "delayed benefit" and the survival advantage in a population completing the induction period, indicate that there is a time lag before CIMAvax-EGF can be effective (17, 28) . A rational combination with chemotherapy can allow the vaccine to "buy" that time. The immunogenicity of CIMAvax-EGF has been already demonstrated in combination with platinum-doublets.
PFS was not a secondary goal of the study, since endpoints based on tumor assessments (response rate, PFS), may not be appropriate for a late phase clinical trial for a cancer vaccine. Previously, other vaccines and immunomodulatory antibodies have not shown improvement in PFS: sipuleucel-T and prostvac-vf in prostate cancer and ipilimumab and eltrapuldencel-T in melanoma were associated with no improvement in PFS and response rate, but statistically significant benefit in overall survival (29) .
The incidence of activating EGFR and ALK translocations was not evaluated in the trial, since the TKI targeting the referred mutations were not accessible. 
